Pharmaceutical composition for the treatment of the decline and/or damage of cognitive functions
OwnerIstvan Gacsalyi, Gyorgy Levay +2inventors
InventorsIstvan Gacsalyi, Gyorgy Levay, Ildiko Nagyne Gyonos, Laszlo Gabor Harsing
Life of this patent
Estimating the term…
Abstract
The compounds of the general Formula (I) (wherein R stands for hydrogen or methyl) can be used for the treatment or prophylaxis of diseases characterized either by the decline and/or damage of cognitive functions, or mental disability accompanying other diseases. As compound of the general Formula I preferably -(1R,2S,4R)-(−)-2-(2-dimethylaminoethoxy)-2-phenyl-1,7,7-trimethylbicyclo[2.2.1]heptane-fumarate can be used. 1
Claims24
Process for the preparation of a pharmaceutical composition comprising a bicycloheptane derivative of the general Formula
- 3
- (wherein R stands for hydrogen or methyl) or a pharmaceutically acceptable acid addition salt thereof which comprises admixing the active ingredient prepared in a known manner with pharmaceutical carriers and/or diluents and finishing in the form of pharmaceutical compositions for the treatment or prophylaxis of diseases characterized either by the decline and/or damage of cognitive functions, or mental disability accompanying other diseases.
Pharmaceutical composition for the treatment or prophylaxis of diseases characterized either by the decline and/or damage of cognitive functions, or mental disability accompanying other diseases comprising as active ingredient a compound of the general Formula I (wherein R stands for hydrogen or methyl) or a pharmaceutically acceptable acid addition salt thereof in admixture with suitable inert solid or liquid pharmaceutical carriers and/or auxiliary agents.
Use of compounds of the general Formula I (wherein R stands for hydrogen or methyl) for the treatment or prophylaxis of diseases characterized either by the decline and/or damage of cognitive functions, or mental disability accompanying other diseases.
Method of treatment or prophylaxis of diseases characterized either by the decline and/or damage of cognitive functions, or mental disability accompanying other diseases which comprises administering to the patient in need of such treatment a pharmaceutically active amount of a compound of the general Formula I or a pharmaceutically acceptable acid addition salt thereof.
Dependencies are inferred from the claim text.